Peg, VicenteLópez-García, María ÁngelesComerma, LauraPeiró, GloriaGarcía-Caballero, TomásLópez, Ángel ConchaSuárez-Gauthier, AnaRuiz, IruneRojo, Federico2023-02-092023-02-092020-12-08http://hdl.handle.net/10668/16754Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. TNBC is characterized by increased expression of Programmed Death-ligand 1 (PD-L1), a signal used by many tumors to escape the immune response. Expression of PD-L1 is a positive predictor of response to immunotherapy; therefore, it should be investigated in TNBC in order to select patients who may benefit from anti-PD-L1 therapies. While many PD-L1 assays are available, only the VENTANA platform with the anti-PD-L1 (SP142) antibody is licensed as a companion diagnostic device for selecting patients with metastatic/advanced TNBC who are candidates for treatment with atezolizumab. In this article, we provide a summary of an expert round-table discussion about PD-L1 testing, using the SP142 antibody in metastatic TNBC.enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/PD-L1antibodybreast cancerdiagnosisimmunohistochemistryimmunotherapyAntibodies, MonoclonalB7-H1 AntigenBiomarkers, TumorClinical Decision-MakingDisease ManagementFemaleHumansImmunohistochemistryMolecular Targeted TherapyNeoplasm MetastasisNeoplasm StagingTriple Negative Breast Neoplasmsresearch article33289433open access10.2217/fon-2020-11001744-8301https://doi.org/10.2217/fon-2020-1100